The International 100K+ Cohorts Consortium: Integrating large-scale cohorts to address global challenges in genomics and precision health
April 15, 2021, 11:00 am -12:00 pm EST
Multiple large cohort studies involving hundreds of thousands of people have recently been launched in several regions worldwide. They are of great value for studying diverse populations and key demographic subgroups, rare genotypes and exposures, and gene-environment interactions. Each cohort is constrained, however, by its size, ancestral origins, and geographic boundaries that limit the subgroups, exposures, outcomes, and interactions it can examine. Combining data across large cohorts to address questions none of them can answer alone enhances the value of each and leverages the enormous investments already made in them to address pressing questions in global health. The International 100K+ Cohorts Consortium (IHCC) comprises 103 cohorts in 43 countries involving nearly 50 million participants.
Collaborative efforts to date have focused on developing a query-able Global Cohorts Atlas and data sharing platform, identifying and piloting high-priority scientific projects, and developing a charter and governance structure to foster collaborations. The current status of the IHCC and plans for the next five years will be discussed.
Geoffrey S. Ginsburg MD, PhD
Professor of Medicine
Duke Center for Applied Genomics and Precision Medicine
Durham, North Carolina
Dr. Ginsburg is the founding director of the Center for Applied Genomics & Precision Medicine at the Duke University Medical Center. He is also the founding director of MEDx, a partnership between the Schools of Medicine and Engineering, created to spark and translate innovation. He is also a Duke University professor of medicine, pathology, and biomedical engineering. Dr Ginsburg has pioneered translational genomics, the development of novel diagnostics, and precision medicine. He has initiated programs in genome-enabled biomarker discovery, longitudinal registries with linked molecular and clinical data, biomarker-informed clinical trials, and the development of novel practice models and implementation research for the integration of genomic tools and digital health technologies into healthcare delivery systems.
- Office of Genomics and Precision Public Health, Office of Science